The cell and gene therapy manufacturing market size is estimated for US$ 3,755.4 million in 2022 to reach an estimate of USD 13,603.4 million by 2032, at a 16.25% CAGR between 2023 and 2032.
Unlock Infinite Advantages: Subscribe to Annual Membership
Considering its potential to treat cancer, cell and gene therapy has sparked a lot of interest. With a complicated and expanding sector, a Contract Development and Manufacturing Company (CDMO) may assist customers in smoothing commercial cell and gene therapy manufacturing needs.
In August 2022, Cytiva, a subsidiary of Danaher Corporation, and Forecyte Bio, a provider of CDMO service designed for cell gene therapy, collaborated to accelerate the development and manufacturing of cell and gene therapies in China and the U.S. Forecyte Bio will use Cytiva’s Flex Factory platform to launch its contract development and manufacturing organization (CDMO) business.
A recent survey on the cell and gene therapy (CGT) industry reveals that while CGT innovators and healthcare providers have had a positive view of the sector over the past 12–18 months (86% and 83%, respectively), contract development and manufacturing organizations (CDMOs) were less optimistic (66%). Looking forward, optimism increases across all groups for the next 12–18 months, with CGT innovators (93%), healthcare providers (86%), and CDMOs (83%) expecting positive developments. Gene therapies are anticipated to have a more favorable outlook compared to autologous and allogeneic cell therapies.
Due to the COVID-19 pandemic, players in the worldwide cell therapy manufacturing industry are experiencing significant hurdles on several fronts. The key obstacles are raw material availability owing to transportation facility inconsistencies. Furthermore, because of the increased prevalence of COVID -19, distributors are experiencing unpredictable demand for products from merchants. However, there has been a modest positive influence on the market since cell therapies for the treatment of COVID-19 are being researched.
According to a Springer Nature article, mesenchymal cells (MSCs) are now being explored as one of the therapeutic strategies for COVID-19 illness. Researchers utilize immunosuppressive medications (Tocilizumab) to treat COVID-19 symptoms in patients; these cells can greatly improve critical circumstances due to their mode of action.
Key Players are involved in developing and launching various types of technologies for cell therapy manufacturing, which is expected to provide immense growth opportunities for industry players in the cell therapy manufacturing market. Manufacturers of cell therapy product candidates are engaged in receiving regulatory approvals to enhance their cell therapy manufacturing process, which in turn is expected to drive the cell therapy manufacturing market growth
One of the most significant issues is the high cost of cell treatments, which has financial consequences for patients, payers, and providers. As a result, firms must lower their pricing in order to increase the acceptance of these medicines, which is projected to hamper market growth throughout the forecast period.
Soon, the cell therapy manufacturing market is likely to rise due to increased investment by major companies in the development of improved cell treatments.
For instance,
The allogeneic cell therapy segment is estimated to be valued at US$ 1,198.2 Mn in 2022 and is expected to reach US$ 3,129.6 Mn by 2030 at a CAGR of 12.8%.
The somatic cell technology segment is estimated to be valued at US$ 823.2 Mn in 2022 and is expected to reach US$ 2,345.6 Mn by 2030 at a CAGR of 14.0%.
IPSC’s (Induced pluripotent stem cell) segment is estimated to be valued at US$ 1,092.5 Mn in 2022 and is expected to reach US$ 4,092.3 Mn by 2030 at a CAGR of 17.9%.
The musculoskeletal segment is estimated to be valued at US$ 807.3 Mn in 2022 and is expected to reach US$ 2,740.2 Mn by 2030 at a CAGR of 16.5%.
The North American cell therapy manufacturing market is estimated to be valued at US$ 1,326.8 Mn in 2022 and is projected to increase to US$ 4,202.0 Mn by 2030, witnessing a CAGR of 15.5% between 2022 and 2030.
| Region | Global Cell Therapy Manufacturing Market Share, By Region, 2022 | Global Cell Therapy Manufacturing Market Share, By Region, 2030 |
| North America | 35.30% | 36.10% |
| Lattin America | 6.10% | 4.90% |
| Europe | 28.10% | 24.80% |
| Asia Pacific | 25.80% | 30.90% |
| Middle East | 3.40% | 2.50% |
| Africa | 1.20% | 0.80% |
| Key Players | Strategies |
| Partnership | On June 15, 2022, WuXi Advanced Therapies, Contract Testing, Development, and Manufacturing Organization (CTDMO) business unit of WuXi AppTec. and Wugen Inc., a clinical-stage biotechnology company, announced a partnership to manufacture Wugen's WU-NK-101, novel immunotherapy that harnesses the power of memory natural killer (NK) cells to treat cancer. WuXi ATU will provide manufacturing and testing services for WU-NK-101 to enable the delivery of this innovative cell therapy product to cancer patients. |
| Announcement | In May, WuXi Advanced Therapies, a contract development and manufacturing organization (CDMO) of WuXi AppTec., announced that it had expanded its service capabilities to offer a fully integrated, closed-process CAR-T cell therapy platform. This new platform will shorten the timeframe for developing, manufacturing, and delivering cell and gene therapies while providing better predictability. |
| Rebranding | In July 2019, BioTime, Inc. announced that it had introduced a new corporate brand, including a change of its corporate name to Lineage Cell Therapeutics, Inc. effective from August 12, 2019. The company also relocated its corporate headquarters to Carlsbad, California, effective August 12, 2019. |
| Collaboration | In June 2018, BioTime Inc. company entered into an agreement with Athersys, Inc., a biotechnology company, for expanding its collaboration in additional therapeutic areas |
| Acquisition | In October 2019, Merck KGaA announced that it had acquired FloDesign Sonics of Wilbraham, Massachusetts, a developer of a unique acoustic cell processing platform, for the industrialization of cell and gene therapy manufacturing |
| Agreement | On June 21, 2021, Takara Bio Inc. announced that it had entered into a license and supply agreement with BioNTech, a Germany-based biotechnology company. Takara Bio grants BioNTech a commercial license to use applicable patents relating to RetroNectin. Under this agreement, Takara Bio provides BioNTech with reliable supplies of RetroNectin, which can be used to manufacture cell and gene therapy products. |
Deepa has certified the degree of Master’s in Pharmacy in the Pharmaceutical Quality Assurance department from Dr D.Y. Patil College of Pharmacy. Her research is focused on the healthcare industry. She is the author or co-author of four Review Articles, which include Solid dispersion a strategic method for poorly soluble drugs and solubility improvement techniques for poorly soluble drugs, Herbal Drugs Used In Treatment Of Cataracts, Nano sponges And Their Application in Cancer Prevention and Ayurvedic Remedies of Peptic ulcer. She has also published a Research Article on the Formulation and Evaluation of Mucoadhesive Tablets of Miconazole cocrystal which was published in GIS Science Journal Volume 9 Issue 8. Her passion for secondary research and desire to take on the challenge of solving unresolved issues is making her flourish is the in the research sector.
